Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 222

Results For "Director"

2485 News Found

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
News | November 10, 2021

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22

Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021


Wockhardt PAT at Rs 33.53 cr. in Q2FY22
News | November 09, 2021

Wockhardt PAT at Rs 33.53 cr. in Q2FY22

The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.


Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22
News | November 09, 2021

Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22

The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Novaerus devices reduce bio-burden in healthcare facilities: Dilip Patil, Partner, Trivector Biomed
interviews | November 05, 2021

Novaerus devices reduce bio-burden in healthcare facilities: Dilip Patil, Partner, Trivector Biomed

Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.


CIMS doctors perform heart transplant on 15-year-old in Ahmedabad
Hospitals | November 05, 2021

CIMS doctors perform heart transplant on 15-year-old in Ahmedabad

The transplant procedure was completed in under two hours


Sun Pharma Q2FY22 PAT jumps to Rs 2088.73 Cr
News | November 03, 2021

Sun Pharma Q2FY22 PAT jumps to Rs 2088.73 Cr

Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.


WHO issues emergency use listing for Covaxin
News | November 03, 2021

WHO issues emergency use listing for Covaxin

This is the eighth Covid-19 vaccine to receive Emergency Use Listing


Caplin Point Labs posts  Q2FY22 PAT at Rs 74.98 Cr
News | November 02, 2021

Caplin Point Labs posts Q2FY22 PAT at Rs 74.98 Cr

The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Thermo Fisher Scientific realigns product portfolio
Medical Device | November 02, 2021

Thermo Fisher Scientific realigns product portfolio

Consolidation of the Acros Organics, Alfa Aesar and Maybridge brands to one single brand, Thermo Scientific


Lyka Labs  Q2FY22 consolidated PAT at Rs. 28.43Cr
News | November 01, 2021

Lyka Labs Q2FY22 consolidated PAT at Rs. 28.43Cr

Lyka Labs has reported consolidated financial results for the period ended September 30, 2021